NVS peer analysis
Novartis (NVS) against its competitors: price, today's move, 1-year return and market value side by side.
NVS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $288.80 | -2.07% | 26.56% | $521.11B |
| AZN AstraZeneca | $186.94 | 0.16% | 13.52% | $289.48B |
| BMY Bristol-Myers Squibb | $62.56 | 0.13% | 37.13% | $127.71B |
| GILD Gilead | $170.72 | 0.02% | 44.14% | $211.70B |
| GSK GSK | $49.08 | -0.88% | 4.55% | $99.19B |
| JNJ Johnson & Johnson | $269.64 | -1.30% | 42.63% | $657.68B |
| MRK Merck | $148.81 | -0.47% | 72.47% | $368.89B |
| NVO Novo Nordisk | $40.71 | 1.77% | -18.65% | $176.43B |
| PFE Pfizer | $30.91 | 1.28% | 27.25% | $173.95B |
| SNY Sanofi | $45.38 | 2.36% | -10.90% | $106.24B |
| NVS Novartis | $161.47 | 0.42% | 31.69% | $303.67B |
- NVS's peers: ABBV (AbbVie), AZN (AstraZeneca), BMY (Bristol-Myers Squibb), GILD (Gilead), GSK (GSK), JNJ (Johnson & Johnson), MRK (Merck), NVO (Novo Nordisk).
Updated 2026-11-02 19:12 UTC